XML 19 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development, net of grant reimbursement $ 23,603 $ 18,526 $ 70,692 $ 50,380
General and administrative 4,276 2,819 12,476 8,703
Total operating expenses 27,879 21,345 83,168 59,083
Operating loss (27,879) (21,345) (83,168) (59,083)
Interest income 2,005 878 6,254 1,223
Other income, net 223 210 616 748
Net loss $ (25,651) $ (20,257) $ (76,298) $ (57,112)
Net loss per share, basic and diluted (in dollars per share) $ (0.61) $ (0.51) $ (1.82) $ (1.43)
Shares used in computing net loss per share, basic and diluted (in shares) 42,002 40,050 41,845 40,009